Table 1.
Selected SBRT clinical trials in head and neck cancer.
| NCT ID | Title | Phase | Patients enrolled | HNSCC population | Number of SBRT fractions | Total dose |
|---|---|---|---|---|---|---|
| NCT02158234 | SBRT and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent HNSCC | 1 | 20 | Re-irradiation of unresectable and recurrent | 5 | 30 Gy |
| NCT05674396 | 3–5 fraction SBRT for Palliation of HNSCC: the FAST Phase II Randomized Trial | 2 | 108 | Ineligible for curative-intent treatment | 3 to 5 | |
| NCT03070366 | SBRT Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC (SBRT + Cx vs SBRT alone) | 2 | 78 | Oligometastatic | 3 or 5 | 30/33/45 Gy or 35/50 Gy |
| NCT04435938 | A Study of SBRT for HNSCC | 2 | 38 | Surgery and standrard RT not recommended/performed | 5 | 45 Gy |
| NCT02057107 | SBRT With Cetuximab ± Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated HNSCC | 2 | 92 | Recurrent, previously-irradiated | 5 | 44–50 Gy |
HNSCC, head and neck squamous cell carcinoma; SBRT, stereotactic body radiation therapy.